CenTNF monoclonal antibody: A 10-patient study in Crohn's disease has been completed, with more than 80 percent of patients showing significant improvement at o

Duration of remission was from six weeks to three months.

A 100-patient Phase II trial is underway, with 20 patients in an open-label protocol and 80 patients in a double-blind protocol. The study is scheduled to finish at year end with results presented in March 1995. ...